Johnson Johnson Aktie
151,20
EUR
+1,16
EUR
+0,77
%
163,54
USD
+0,53
USD
+0,33
%
Es gab keine Analysen zu dieser Aktie in den letzten sechs Monaten.
Kursziele der Johnson Johnson-Aktie in
Das durchschnittliche Kursziel beinhaltet alle Analysen eines Analysten und nicht nur die jeweils aktuellste Analyse, die im Chart dargestellt wird.
Werbung
Kursziele im Branchenvergleich
| Aktie | Buy | Hold | Sell | Ø Kursziel | Abst. Kursziel |
|---|---|---|---|---|---|
| Abbott Laboratories | 0 | 0 | 0 | - | - |
| Alexion Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Allergan Inc. | 0 | 0 | 0 | - | - |
| APONTIS PHARMA | 0 | 0 | 0 | - | - |
| AstraZeneca PLC | 6 | 3 | 0 | 139,58 GBP | - |
| Bayer | 1 | 8 | 0 | 24,88 EUR | +3,24% |
| Beiersdorf AG | 8 | 1 | 2 | 146,00 EUR | +14,51% |
| BioNTech (ADRs) | 4 | 2 | 0 | 131,67 USD | +38,05% |
| CanSino Biologics Inc. Registered Shs -A- | 0 | 0 | 0 | - | - |
| Celgene Corp. | 0 | 0 | 0 | - | - |
| CureVac | 0 | 1 | 0 | - | - |
| Douglas | 4 | 0 | 0 | 28,00 EUR | +145,61% |
| Fresenius Medical Care (FMC) St. | 3 | 5 | 2 | 45,17 EUR | +0,71% |
| Fresenius SE & Co. KGaA (St.) | 8 | 1 | 0 | 43,86 EUR | +10,51% |
| GSK PLC Registered Shs | 2 | 6 | 1 | 16,62 GBP | +10,14% |
| Johnson & Johnson | 0 | 0 | 0 | - | - |
| Merck Co. | 0 | 0 | 0 | - | - |
| Merck KGaA | 7 | 1 | 0 | 180,57 EUR | +37,11% |
| Moderna Inc | 0 | 2 | 1 | 67,33 USD | +106,15% |
| MorphoSys | 0 | 1 | 0 | 68,00 EUR | - |
| Nestlé SA (Nestle) | 3 | 7 | 1 | 85,00 CHF | -7,29% |
| Novartis AG | 3 | 5 | 1 | 99,12 CHF | -0,11% |
| Novavax Inc. | 0 | 0 | 0 | - | - |
| Pfizer Inc. | 3 | 3 | 0 | 30,20 USD | +14,92% |
| Procter & Gamble Co. | 0 | 0 | 0 | - | - |
| Roche Holding AG (Inhaberaktie) | 0 | 0 | 0 | - | - |
| Sanofi S.A. | 6 | 3 | 0 | 115,50 EUR | +9,09% |
| Shanghai Fosun Pharmaceutical (Group) Co Ltd (A) | 0 | 0 | 0 | - | - |
| Sinopharm Group Co Ltd (H) | 0 | 0 | 0 | - | - |
| Sinovac Biotech LtdShs | 0 | 0 | 0 | - | - |
| STADA | 0 | 0 | 0 | - | - |
| Unilever plc | 6 | 1 | 3 | 47,50 GBP | +4,26% |
| Valneva | 0 | 0 | 0 | - | - |